Megan Giboney - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Megan Giboney's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Megan Giboney
Verified
Digital Editor, RegMedNet
Beats
body,Mental health LGBTQ+ issues, relationships money, health work, identity women's issues, sex
Anything about soccer.
Content
By Megan Giboney| RegMedNet@ This week: Applied StemCell (CA, USA) submitted a Type II Drug Master File (DMF) to the US Food and Drug Administration (FDA; MD, USA) for its GMP-grade human induced pluripotent stem cell (hiPSC) line, Fate Therapeutics (CA, USA) received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its iPSC-derived CAR T-therapy for systemic lupus erythematosus, and Cellino (MA, USA) and Karis Bio (Seoul, South Korea) announced a strategic partnership to manufacture an...
World Parkinson’s Day: advancing treatment options with cell therapies, gene therapies and novel biologics
By Megan Giboney| RegMedNet@ Over 11 million people worldwide are estimated to live with Parkinson’s disease, the fastest growing neurological condition in the world. Taking place annually on 11 April, World Parkinson’s Day aims to promote research and support for those living with the condition. Parkinson’s disease, a progressive neurodegenerative disorder characterized by tremors, stiffness and slowed movement, is primarily caused by the loss of dopamine-producing neurons in the brain.
By Megan Giboney| RegMedNet@ This week: Applied StemCell (CA, USA) submitted a Type II Drug Master File (DMF) to the US Food and Drug Administration (FDA; MD, USA) for its GMP-grade human induced pluripotent stem cell (hiPSC) line, Fate Therapeutics (CA, USA) received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its iPSC-derived CAR T-therapy for systemic lupus erythematosus, and Cellino (MA, USA) and Karis Bio (Seoul, South Korea) announced a strategic partnership to manufacture an...
Company Info
RegMedNet
Oncology Central, part of Taylor Francis, is a free online platform that is dedicated to advancing oncology by offering access to trusted, engaging and insightful resources – including breaking news, peer-reviewed articles, webinars and articles from key opinion leaders. By providing 360° perspectives on the latest advancements – encompassing the viewpoints of industry, clinicians, researchers, charities and patients alike – we are very proud to have established Oncology Central as a key resource for the global oncology community.
London, United Kingdom
+44 20 8371 6090